- Antibodies
- Cell Therapies
- Vaccines
- Others
Biologics Contract Manufacturing Market size was valued at USD 19,250.6 million in 2023 and is poised to grow at a 9.4% CAGR from 2024 to 2030. The COVID-19 epidemic in 2020 caused unparalleled growth. The main driving factors behind this expansion were the government's and major biopharmaceutical companies' increased investments aimed at boosting efficiency and productivity. Biologics outsourcing in biotechnology has emerged as a new trend. Orders and requests for biotech contract manufacturing are rising, mostly for coronavirus vaccines and treatments. More than forty queries concerning COVID-19-related projects have been received by Lonza. The supply chain is disrupted as a result of the COVID-19 epidemic.
Study Period
2024-2030Base Year
2023CAGR
9.4%Largest Market
North AmericaFastest Growing Market
Asia Pacific
Continuous advances in biotechnology and biomedical science approaches have significantly improved the process of developing biologics for the treatment of a variety of chronic diseases. Recent advances in biologics are targeted at improving cell line development, protein identification, expression, and engineering. Several new technologies for producing self-adjuvating antigen-adjuvant fusion protein subunit vaccines have emerged in recent years. The availability of described platforms of new adjuvants has been shown to benefit in the development of novel vaccines. Furthermore, the usage of Nano systems has grown in recent years as a means of addressing delivery problems associated with the use of mRNA therapies in disease therapy. Nonetheless, supply chains have shown to be resilient, and worldwide supplies, manufacturing, and services related to biologics have not been significantly impacted. Several factors, including a strong pipeline of biologics, a rise in FDA NDA/BLA approvals, an increase in patent expirations, limited manufacturing capacity, and the need to realize cost savings, have led industry participants to choose contract manufacturing services for the development of biologics in order to remain competitive.
By product type
By Company Size
The global biologics contract manufacturing market size was valued at US$ 19,250.6 million in 2023 and is projected to grow at a CAGR of 9.4% by 2030.
The rapid development of biologics has transformed the treatment of a wide range of therapeutic problems, contributing to the current exponential surge in demand for biological medicines.
The pharmaceutical industry appears to be embracing the era of biologics given the continuous advances in science and the growth of FDA-approved biologics.
Market research is segmented based on product type, company size and region.
North America is estimated to dominate with the highest CAGR over the forecast period.
1.Executive Summary |
2.Global Biologics Contract Manufacturing Market Introduction |
2.1.Global Biologics Contract Manufacturing Market - Taxonomy |
2.2.Global Biologics Contract Manufacturing Market - Definitions |
2.2.1.product type |
2.2.2.Company Size |
2.2.3.Region |
3.Global Biologics Contract Manufacturing Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Biologics Contract Manufacturing Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Biologics Contract Manufacturing Market By product type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Antibodies |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Cell Therapies |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Vaccines |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Others |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6.Global Biologics Contract Manufacturing Market By Company Size , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Small |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Mid-sized |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Large |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7.Global Biologics Contract Manufacturing Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8.North America Biologics Contract Manufacturing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. product type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.Antibodies |
8.1.2.Cell Therapies |
8.1.3.Vaccines |
8.1.4.Others |
8.2. Company Size Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Small |
8.2.2.Mid-sized |
8.2.3.Large |
8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9.Europe Biologics Contract Manufacturing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. product type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Antibodies |
9.1.2.Cell Therapies |
9.1.3.Vaccines |
9.1.4.Others |
9.2. Company Size Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Small |
9.2.2.Mid-sized |
9.2.3.Large |
9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
10.Asia Pacific (APAC) Biologics Contract Manufacturing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. product type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Antibodies |
10.1.2.Cell Therapies |
10.1.3.Vaccines |
10.1.4.Others |
10.2. Company Size Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Small |
10.2.2.Mid-sized |
10.2.3.Large |
10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11.Middle East and Africa (MEA) Biologics Contract Manufacturing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. product type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Antibodies |
11.1.2.Cell Therapies |
11.1.3.Vaccines |
11.1.4.Others |
11.2. Company Size Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Small |
11.2.2.Mid-sized |
11.2.3.Large |
11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12.Latin America Biologics Contract Manufacturing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. product type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Antibodies |
12.1.2.Cell Therapies |
12.1.3.Vaccines |
12.1.4.Others |
12.2. Company Size Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Small |
12.2.2.Mid-sized |
12.2.3.Large |
12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.Wuxi Biologics |
13.2.2.Abzena Ltd. |
13.2.3.Fujifilm Inc. |
13.2.4.Boehringer Ingelheim GmbH |
13.2.5.Lonza |
13.2.6.Vetter |
13.2.7.Almac |
13.2.8.Catalent |
13.2.9.Reddy’s |
13.2.10.Thermo Fischer (Patheon) |
13.2.11.Farmar SA |
14. Research Methodology |
15. Appendix and Abbreviations |